Buradasınız

Anasayfa » Content

Çocukluk Çağında Tümör Lizis Sendromu

Tumor Lysis Syndrome in Childhood

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Tumor lysis syndrome (TLS) is a clinical condition that results from rapid destruction of the tumor cells and it is associated with life-threatening metabolic abnormalities. These metabolic abnor¬malities are hyperuricemia, hyperkalemia, hyperphosphatemia and secondary development of hypocalcemia. TLS is seen most frequ¬ently in patients with lymphoproliferative malignancies. The most important point of treatment is early identification of patients that are at risk for the development of TLS and its prevention. Nephrology clinics are closely interested in TLS because generally the metabolic abnormalities occur together with the acute renal failure. This review focuses on basic background information, pat-hogenesis and preventive as well as therapeutic strategies concer¬ning TLS.
Bookmark/Search this post with
Abstract (Original Language): 
Tümör lizis sendromu (TLS), tümör hücrelerinin hızlı bir şekilde yıkılmasıyla ortaya çıkan ve yaşamı tehdit edebilen metabolik anormalliklerle seyreden bir klinik tablodur. Bu metabolik anormallikler hiperürisemi, hiperkalemi, hiperfosfatemi ve buna ikincil ortaya çıkan hipokalsemidir. Sendrom sıklıkla lenfoproliferatif malign hastalıklı hastalarda görülür. Riskli hastaların erken belirlenmesi ve TLS gelişiminin önlenmesi tedavinin en önemli bölümüdür. Tanımlanan metabolik bozuklukların yanında akut böbrek yetmezliği (ABY) gelişme riskinin yüksek olması nedeniyle nefroloji klinikleri¬ni yakından ilgilendirmektedir. Bu yazıda TLS hakkında temel bilgi¬ler, patogenez ve tedavi yöntemleri ile önleyici girişimler sunul¬maktadır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_520.pdf
  • 2
57-61
  • Turkish

REFERENCES

References: 

1. Haas M, Öhler L, Watzke H, Böhmig G, Prokesch R, Druml W. The spectrum of acute renal failure in tumour lysis syndrome. Nephrol Dial Transplant 1999;14:776-779.
2. Rheingold SR, Lange BJ. Oncologic emergencies. In: Pizzo PA, Poplack GD, Principles and Practice of Pediatric Oncology (4th ed). Lippincott Williams & Wilkins, Philadelphia, 2002, pp 1177-1203.
3. Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta 2003;333: 13-18.
4. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, clinical consequences, and tre¬atment of tumor lysis syndrome. Am J Med 2004;116:546-554.
5. Patte C, Sakiroglu C, Ansoborlo S, et al. Urate-oxidase in the prevention and treatment of metabolic complications in pati¬ents with B-cell lymphoma and leukemia, treated in the So-ciete Francaise d'Oncologie Pediatrique LMB89 protocol. Ann Oncol 2002;13:789-795.
6. Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995;9:206-212.
7. Flombaum CD. Metabolic emergencies in the cancer patient.
Semin Oncol 2000;27:322-334.
8. Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor--how to manage the problem. Nephrol Dial Transplant 2002;17 [Suppl 11]:16-19.
9. Schwartz GJ. Potassium. In: Avner ED, Harmon WE, Niaudet P (eds), Pediatric Nephrology (5th ed). Lippincott Williams & Wilkins, Philadelphia, 2004, pp 147-188.
10. Hain RD, Harvey E, Poon AO, Weitzman S. Acute tumour lysis syndrome with no evidence of tumour load. Pediatr Nephrol 1994;8:537-539.
11. Parisi MT, Fahmy JL, Kaminsky CK, Malogolowkin MH.
Complications of cancer therapy in children: a radiologist's guide. Radiographics 1999;19:283-297.
12. Wolf G, Hegewisch-Becker S, Hossfeld DK, Stahl RA. Hype-
ruricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis 1999;34:E20.
13. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomi¬zed comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor
lysis. Blood 2001;97:2998-3003.
14. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in pre¬vention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11:1813-1816.
15. Brant JM. Rasburicase: an innovative new treatment for hype-ruricemia associated with tumor lysis syndrome. Clin J Oncol
Nurs 2002;6:12-16.
16. Lee AC, Li CH, So KT, Chan R. Treatment of impending tu¬mor lysis with single-dose rasburicase. Ann Pharmacother
2003;37:1614-1617.
17. Andreoli SP. Clinical evaluation and management. In: Avner ED, Harmon WE, Niaudet P (eds), Pediatric Nephrology (5th ed). Lippincott Williams & Wilkins, Philadelphia, 2004, pp
1233-1251.
18. McClure RJ, Prasad VK, Brocklebank JT. Treatment of hyper-kalaemia using intravenous and nebulised salbutamol. Arch
Dis Child 1994;70:126-128.
19. Annemans L, Moeremans K, Lamotte M, et al. Incidence, me¬dical resource utilisation and costs of hyperuricemia and tu¬mour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk
Lymphoma 2003;44:77-83.
20. Strazdins V, Watson AR, Harvey B; European Pediatric Peri¬toneal Dialysis Working Group. Renal replacement therapy for acute renal failure in children: European guidelines. Pe-
diatr Nephrol 2004;19:199-207.
21. Sewani HH, Rabatin JT. Acute tumor lysis syndrome in a pa¬tient with mixed small cell and non-small cell tumor. Mayo
Clin Proc 2002;77:722-728.

Thank you for copying data from http://www.arastirmax.com